Elanco Animal Health Inc (ELAN) stock
ELANNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 9/30129% above fair value
$25.85−0.56 (-2.12%)
Close on Nov 17, 2026Market cap $12.92BP/E –Yield –
Elanco Animal Health cash
Cash and short-term investments held at the end of each period.
Elanco Animal Health's cash was $530.00M at Jun 30, 2026. For fiscal 2025 it was $545.00M, up 16.5% from the year before. Over ten years it grew 1.7% a year on average. The highest annual figure on record is $678.00M in fiscal 2018.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $545.00M | +16.5% |
| FY2024 | Dec 31, 2024 | $468.00M | +33.0% |
| FY2023 | Dec 31, 2023 | $352.00M | +2.0% |
| FY2022 | Dec 31, 2022 | $345.00M | -45.9% |
| FY2021 | Dec 31, 2021 | $638.00M | +26.1% |
| FY2020 | Dec 31, 2020 | $506.00M | +46.7% |
| FY2019 | Dec 31, 2019 | $345.00M | -49.1% |
| FY2018 | Dec 31, 2018 | $678.00M | +109.6% |
| FY2017 | Dec 31, 2017 | $323.40M | +25.0% |
| FY2016 | Dec 31, 2016 | $258.80M | -43.8% |
| FY2015 | Dec 31, 2015 | $460.60M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $530.00M | -1.7% |
| Q1 FY2026 | Mar 31, 2026 | $428.00M | -12.1% |
| Q4 FY2025 | Dec 31, 2025 | $545.00M | +16.5% |
| Q3 FY2025 | Sep 30, 2025 | $505.00M | +3.1% |
| Q2 FY2025 | Jun 30, 2025 | $539.00M | +29.6% |
| Q1 FY2025 | Mar 31, 2025 | $487.00M | +41.2% |
| Q4 FY2024 | Dec 31, 2024 | $468.00M | +33.0% |
| Q3 FY2024 | Sep 30, 2024 | $490.00M | +32.8% |
| Q2 FY2024 | Jun 30, 2024 | $416.00M | +13.4% |
| Q1 FY2024 | Mar 31, 2024 | $345.00M | +8.5% |
| Q4 FY2023 | Dec 31, 2023 | $352.00M | +2.0% |
| Q3 FY2023 | Sep 30, 2023 | $369.00M | -19.8% |
| Q2 FY2023 | Jun 30, 2023 | $367.00M | -27.6% |
| Q1 FY2023 | Mar 31, 2023 | $318.00M | -7.0% |
| Q4 FY2022 | Dec 31, 2022 | $345.00M | -45.9% |
| Q3 FY2022 | Sep 30, 2022 | $460.00M | +1.5% |
| Q2 FY2022 | Jun 30, 2022 | $507.00M | -12.6% |
| Q1 FY2022 | Mar 31, 2022 | $342.00M | -33.6% |
| Q4 FY2021 | Dec 31, 2021 | $638.00M | +26.1% |
| Q3 FY2021 | Sep 30, 2021 | $453.00M | -31.4% |
| Q2 FY2021 | Jun 30, 2021 | $580.00M | -58.3% |
| Q1 FY2021 | Mar 31, 2021 | $515.00M | -57.3% |
| Q4 FY2020 | Dec 31, 2020 | $506.00M | +46.7% |
| Q3 FY2020 | Sep 30, 2020 | $660.00M | +113.5% |
| Q2 FY2020 | Jun 30, 2020 | $1.39B | +261.2% |
| Q1 FY2020 | Mar 31, 2020 | $1.21B | +343.2% |
| Q4 FY2019 | Dec 31, 2019 | $345.00M | -49.1% |
| Q3 FY2019 | Sep 30, 2019 | $309.20M | +3.1% |
| Q2 FY2019 | Jun 30, 2019 | $385.10M | +20.0% |
| Q1 FY2019 | Mar 31, 2019 | $272.10M | +3.3% |
| Q4 FY2018 | Dec 31, 2018 | $678.00M | +109.6% |
| Q3 FY2018 | Sep 30, 2018 | $300.00M | -12.7% |
| Q2 FY2018 | Jun 30, 2018 | $321.00M | +24.0% |
| Q1 FY2018 | Mar 31, 2018 | $263.40M | -42.8% |
| Q4 FY2017 | Dec 31, 2017 | $323.40M | – |
| Q3 FY2017 | Sep 30, 2017 | $343.60M | – |
| Q4 FY2016 | Dec 31, 2016 | $258.80M | – |
| Q4 FY2015 | Dec 31, 2015 | $460.60M | – |
See a number that looks wrong?